Nucleus

Lab of Institute Scholar Monther Abu-Remaileh has built an atlas of proteins associated with lysosomes in different brain cell types that researchers hope will shed light on neurodegenerative disease.

A Stanford-led study found that tegavivint, a drug candidate already in clinical trials, causes a new type of cancer cell death. The findings could inform future use of tegavivint

Oxidizing chemicals break this cellular power plant into bits, causing Parkinson’s, ALS, heart disease, diabetes, and cancer—but a molecule could block the process.

Developed by Director of Medicinal Chemistry Mark Smith, the new method could make it possible for chemotherapy patients to take pills rather than receive IV infusions.

A promising novel drug candidate, designed at the atomic level, could help doctors halt the rise of lethal new drug resistant SARS-CoV-2 variants.

Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could enable the development of new cancer treatments.

Through c-ShARP, Stanford researchers get access to top-notch scientific facilities across campus, including the Nucleus at Sarafan ChEM-H.

A new study found that part of the Epstein-Barr virus mimics a protein made in the brain and spinal cord, leading the immune system to mistakenly attack the body’s nerve cells.

Researchers at Stanford are working to develop a single-dose vaccine for SARS-CoV-2 that could potentially be stored at room temperature.

Chemistry Professor Carolyn Bertozzi says recruiting world-class scientists and engineers and developing ChEM-H into a hub where doctors and researchers can come together.